EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular Degeneration (AMD). They have discovered that controlling an inflammatory component IL-18, in cases of Age-Related Macular Degeneration (AMD) could prevent…
Avalanche Biotechnologies, Inc. (“Avalanche”) (AAVL) and Annapurna Therapeutics SAS (“Annapurna”), a privately held biopharmaceutical company, today announced that they have entered into a definitive agreement providing for the acquisition of all outstanding shares of Annapurna by Avalanche in exchange for approximately 17.6 million newly issued shares of Avalanche common stock. Upon completion of the proposed…
“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
“NEW YORK (Reuters Health) – In patients with unilateral neovascular age-related macular degeneration (AMD), certain drusen features are associated with conversion to neovascular AMD in the fellow eye, according to a secondary analysis of data from a clinical trial. Dr. Joelle A. Hallak of the University of Illinois at Chicago and colleagues used machine learning…
The first human genome sequencing was accomplished after 13 painstaking years of research at the cost of $3 billion. But recent advances in sequencing technology holds promise of rapid increase in speed of sequencing at the rate of 6 billion nucleotide bases every 6 h at a cost below $1000. http://www.azonano.com/news.aspx?newsID=24912
RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is a genetic condition which leads to the progressive degeneration of rod and cone photoreceptors (cells found in…